Compare ACON & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | ALBT |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 5.9M |
| IPO Year | 2022 | N/A |
| Metric | ACON | ALBT |
|---|---|---|
| Price | $6.44 | $1.34 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 59.9K | 57.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,483.00 | ★ $1,611,940.00 |
| Revenue This Year | $145.39 | N/A |
| Revenue Next Year | $145.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.91 | N/A |
| 52 Week Low | $5.55 | $1.21 |
| 52 Week High | $3,499.49 | $11.66 |
| Indicator | ACON | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 38.71 |
| Support Level | $5.71 | $1.37 |
| Resistance Level | $6.89 | $1.77 |
| Average True Range (ATR) | 0.61 | 0.20 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 35.04 | 23.21 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.